Integrum AB Class B AI Stock Analysis
Want to see SE:INTEG.B full AI Analyst Report?
Integrum AB Class B (INTEG.B) AI Stock Analysis
Integrum AB Class B
(Nasdaq OMX AB:INTEG.B)
The score is held down primarily by weak financial performance—unstable profitability, negative gross profit, and ongoing operating/free-cash-flow burn—despite a low-debt balance sheet. Technicals provide a partial offset with price trading above key moving averages and a positive MACD, but valuation support is limited given negative earnings and no stated dividend yield.
Integrum AB Class B (INTEG.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 240.25M
- Dividend Yield
- ―
- Average Volume (3M)
- 47.85K
- Price to Earnings (P/E)
- -5.7
- Beta (1Y)
- 0.87
- Revenue Growth
- 1.43%
- EPS Growth
- 4.98%
- Country
- Sweden
- Employees
- 33
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Integrum AB Class B Business Overview & Revenue Model
Company Description
Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bone-...
Integrum AB Class B Financial Statement Overview
Summary
Financials are mixed but skew negative: revenue growth is meaningful, and the balance sheet is strong with very low leverage (debt-to-equity ~1.6%). However, profitability has deteriorated sharply (TTM negative gross profit and deeply negative operating/net margins) and cash generation is weak with materially negative operating cash flow and free cash flow, increasing funding dependence if losses persist.
Income Statement
26NegativeBalance Sheet
72PositiveCash Flow
22Negative| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 97.81M | 91.39M | 91.10M | 104.12M | 74.27M | 55.72M |
| Gross Profit | -1.75M | 63.23M | 75.38M | 91.26M | 60.84M | 46.56M |
| EBITDA | -25.61M | -39.62M | -35.50M | 8.76M | -20.24M | 2.60M |
| Net Income | -35.50M | -46.34M | -30.85M | 4.03M | -16.18M | 21.27M |
Balance Sheet | ||||||
| Total Assets | 199.15M | 203.60M | 203.25M | 164.86M | 165.17M | 180.44M |
| Cash, Cash Equivalents and Short-Term Investments | 15.01M | 19.06M | 39.60M | 16.90M | 41.92M | 75.34M |
| Total Debt | 2.74M | 3.17M | 4.84M | 6.42M | 7.92M | 580.89K |
| Total Liabilities | 24.96M | 31.59M | 25.38M | 22.07M | 21.64M | 20.70M |
| Stockholders Equity | 174.19M | 172.01M | 177.88M | 142.79M | 143.53M | 159.74M |
Cash Flow | ||||||
| Free Cash Flow | -43.10M | -57.96M | -50.59M | -24.37M | -36.50M | -49.55M |
| Operating Cash Flow | -33.67M | -41.02M | -37.70M | -12.74M | -25.10M | -20.28M |
| Investing Cash Flow | -16.44M | -16.94M | -12.89M | -11.63M | -11.40M | -29.27M |
| Financing Cash Flow | 37.92M | 37.43M | 73.29M | -648.54K | 3.08M | 117.23M |
Integrum AB Class B Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Negative. The current price of 8.19 is below the 20-day moving average (MA) of 8.36, below the 50-day MA of 8.79, and below the 200-day MA of 8.28, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 41.58 is Neutral, neither overbought nor oversold. The STOCH value of 62.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:INTEG.B.
Integrum AB Class B Peers Comparison
Overall Rating
SE:SECT.B74Outperform
SE:GETI.B67Neutral
SE:SEZI55Neutral
SE:BACTI.B53Neutral
SE:INTEG.B49Neutral
SE:OSSD45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | SEK 62.79B | 98.41 | 30.26% | 0.71% | 13.94% | 5.70% | |
| 67Neutral | SEK 76.70B | 27.10 | 9.13% | 1.69% | -3.90% | 37.73% | |
| 55Neutral | SEK 551.04M | -5.65 | -35.44% | ― | 18.56% | 28.11% | |
| 53Neutral | SEK 537.92M | 85.28 | 1.93% | ― | -0.51% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | SEK 240.25M | -5.70 | -20.71% | ― | 1.43% | 4.98% | |
| 45Neutral | SEK 387.19M | -7.74 | ― | ― | -11.89% | -11.85% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:INTEG.B | Integrum AB Class B | 8.19 | -0.04 | -0.49% | |
| SE:GETI.B | Getinge AB (UK) | 281.60 | 74.49 | 35.96% | |
| SE:SEZI | Senzime AB | 3.50 | -1.75 | -33.24% | |
| SE:BACTI.B | Bactiguard Holding AB | 15.35 | -0.55 | -3.46% | |
| SE:SECT.B | Sectra AB Class B | 321.80 | 36.48 | 12.78% | |
| SE:OSSD | OssDsign AB | 3.50 | -7.48 | -68.12% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026
